Basilea Pharmaceutica Forecast, price target & analysts
Basilea Pharmaceutica Target price 2025 - Analyst rating & recommendation
Basilea Pharmaceutica Classifications & Recommendation:
Basilea Pharmaceutica Price Target
| Target Price | CHF70.38 |
| Price | CHF46.85 |
| Potential |
50.22%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Basilea Pharmaceutica 2026 .
The average Basilea Pharmaceutica target price is CHF70.38.
This is
50.22%
register free of charge
CHF110.25
135.33%
register free of charge
CHF64.64
37.97%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Basilea Pharmaceutica to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Basilea Pharmaceutica stock has an average upside potential 2026 of
50.22%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million CHF | 208.54 | 224.00 |
| 32.30% | 7.41% | |
| EBITDA Margin | 30.17% | 23.07% |
| 128.84% | 23.53% | |
| Net Margin | 37.21% | 17.32% |
| 461.23% | 53.45% |
9 Analysts have issued a sales forecast Basilea Pharmaceutica 2025 . The average Basilea Pharmaceutica sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Basilea Pharmaceutica EBITDA forecast 2025. The average Basilea Pharmaceutica EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Basilea Pharmaceutica Analysts have issued a net profit forecast 2025. The average Basilea Pharmaceutica net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 5.60 | 3.16 |
| 543.68% | 43.57% | |
| P/E | 14.83 | |
| EV/Sales | 2.37 |
9 Analysts have issued a Basilea Pharmaceutica forecast for earnings per share. The average Basilea Pharmaceutica EPS is
This results in the following potential growth metrics and future valuations:
Basilea Pharmaceutica...
Current Basilea Pharmaceutica Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
| H.C. WAINWRIGHT & CO., LLC |
Locked
➜
Locked
|
Locked | Jul 07 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | May 20 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | May 19 2025 |
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Jul 08 2025 |
|
Locked
H.C. WAINWRIGHT & CO., LLC:
Locked
➜
Locked
|
Jul 07 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
May 19 2025 |
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Mar 26 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
